Physician profile
Arthur L Berman
NPI 1730273236
$21,459.79
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $6,077 · 2021: $10K · 2022: $4,592.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $19,662.59 | 2020-2022 | |
| Abbvie INC. | $550.65 | 2019-2021 | |
| Alfasigma USA, INC. | $526.96 | 2020 | |
| Janssen Biotech, INC. | $113.86 | 2019-2020 | |
| Boston Scientific Corporation | $102.66 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.20 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $84.50 | 2022 | |
| Gilead Sciences, INC. | $83.27 | 2019-2021 | |
| Pfizer INC. | $66.01 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.44 | 2019 | |
| Ironwood Pharmaceuticals, INC | $36.78 | 2019-2020 | |
| Allergan, INC. | $16.51 | 2019 | |
| Shire North American Group INC | $14.49 | 2019 | |
| Intercept Pharmaceuticals, INC. | $14.42 | 2020 | |
| Merck Sharp & Dohme LLC | $13.15 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $11.96 | 2019 | |
| Braintree Laboratories, INC. | $11.92 | 2021 | |
| Ucb, INC. | $11.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.